| 39 | DIRECTORS' REMUNERATION AND INTERESTS |
Directors' remuneration The group remuneration philosophy and basis for determining performance bonuses is set out in the remuneration report. Other benefits determined below include share purchase trust loans, expatriate benefits, retention payments, redundancy and termination payments and any other non-pensionable allowances or fringe benefits. The directors' and prescribed officers' remuneration for the year ended 30 September 2020 was as follows:
Interest of directors and prescribed officers of the company in share capital The aggregate beneficial holdings as at 30 September 2020 of the directors and prescribed officers of the company and their immediate families (none of which has a holding in excess of 1%) in the issued ordinary shares of the company are detailed below. There have been no material changes in these shareholdings since that date. |
| Khula Sizwe | Barloworld | |||||||||||
| 2020 | 2020 | 2020 | 2020 | 2020 | 2020 | 2020 | 2020 | 2019 | 2019 | 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of shares at 30 September | Management Trust |
Public Scheme – Direct |
Public Scheme – Indirect |
CSP | Forfeitable | Direct | Indirect | Total | Forfeitable | Direct | Indirect | |
| Executive directors | ||||||||||||
| DM Sewela | 3 214 915 | 104 420 | 93 700 | 18 442 | 171 519 | 388 081 | 112 860 | 18 442 | 77 638 | |||
| NV Lila | 696 076 | 37 690 | 14 540 | 52 230 | ||||||||
| DG Wilson | 124 197 | |||||||||||
| Total executive directors | 3 910 991 | 142 110 | 108 240 | 18 442 | 171 519 | 440 311 | 112 860 | 142 639 | 77 638 | |||
| Non-executive directors | ||||||||||||
| NP Dongwana | 10 000 | |||||||||||
| N Mokhesi | 1 500 | |||||||||||
| S Ntsaluba | 10 000 | 5 155 | 2 280 | 7 435 | 5 155 | |||||||
| DB Ntsebeza | 40 000 | 48 864 | 48 864 | 48 864 | ||||||||
| P Schmidt | 28 000 | 28 000 | ||||||||||
| IO Shongwe | 89 277 | 3 184 | ||||||||||
| S Mkhabela | 37 430 | |||||||||||
| Total non-executive directors | 61 500 | 82 019 | 2 280 | 84 299 | 180 726 | 3 184 | ||||||
| Prescribed officers | ||||||||||||
| E Leeka | 1 131 304 | 41 320 | 37 260 | 51 785 | 130 365 | 42 050 | 41 302 | |||||
| K Mmutlana | 1 080 078 | 37 690 | 27 520 | 24 558 | 89 768 | 45 780 | 7 326 | |||||
| Total prescribed officers | 2 211 382 | 79 010 | 64 780 | 76 343 | 220 133 | 87 830 | 48 628 | |||||
| Grand total | 6 122 373 | 61 500 | 221 120 | 173 020 | 176 804 | 173 799 | 744 743 | 200 690 | 371 993 | 80 822 | ||
Interest of directors and prescribed officers of the company in share options, share appreciation rights and forfeitable shares The interests of the executive directors and prescribed officers in shares of the company provided in the form of options, share appreciation rights and forfeitable shares are shown in the table below: |
| Award date | Number allocated in prior years | Number allocated in current year | Number exercised (options and SAR)/vested (FSP) /lapsed in current year | Closing number | Exercise price | Price on exercise date (options and SAR) /vesting price (FSP) | Exercise or exercisable (options and SAR)/vesting date (FSP) |
| Executive directors | |||||||
| DM Sewela | |||||||
| Share appreciation rights | |||||||
| 2016 | 65 350 | 65 350 | 72.77 | 29-Mar-19 | |||
| 2017 | 85 920 | 85 920 | 121.53 | 28-Mar-20 | |||
| 2018 | 137 540 | 137 540 | 177.71 | 29-Jan-21 | |||
| 2019 | 189 340 | 189 340 | 130.02 | 26-Feb-22 | |||
| FSP – no performance conditions | |||||||
| 2017 | 14 860 | 14 860 | n/a | 71.5 | 28-Mar-20 | ||
| 2018 | 5 480 | 5 480 | n/a | 29-Jan-21 | |||
| 2019 | 7 880 | 7 880 | n/a | 26-Feb-22 | |||
| 2020 | 10 070 | 10 070 | n/a | 8-Mar-23 | |||
| FSP – with performance conditions | |||||||
| 2017 | 44 580 | 41 335 | 3 245 | n/a | 71.50 | 23-Mar-20 | |
| 2017 | 3 245 | (3 245) | n/a | Lapsed | 23-Mar-20 | ||
| 2018 | 16 430 | 16 430 | n/a | 29-Jan-21 | |||
| 2019 | 23 630 | 23 630 | n/a | 26-Feb-22 | |||
| 2020 | 30 210 | 30 210 | n/a | 8-Mar-23 | |||
| CSP | |||||||
| 2020 | 104 420 | 104 420 | n/a | 8-Mar-23 | |||
| NV Lila | |||||||
| FSP – no performance conditions | |||||||
| 2020 | 3 640 | 3 640 | n/a | 8-Mar-23 | |||
| FSP – with performance conditions | |||||||
| 2020 | 10 900 | 10 900 | n/a | 8-Mar-23 | |||
| CSP | |||||||
| 2020 | 37 690 | 37 690 | n/a | 8-Mar-23 | |||
| Prescribed officers | |||||||
| E Leeka | |||||||
| Share appreciation rights | |||||||
| 2017 | 29 950 | 29 950 | 121.53 | 28-Mar-20 | |||
| 2018 | 55 270 | 55 270 | 177.71 | 29-Jan-21 | |||
| 2019 | 75 330 | 75 330 | 130.02 | 26-Feb-22 | |||
| FSP – no performance conditions | |||||||
| 2017 | 5 180 | 5 180 | n/a | 23-Mar-20 | |||
| 2018 | 2 200 | 2 200 | n/a | 29-Jan-21 | |||
| 2019 | 3 130 | 3 130 | n/a | 26-Feb-22 | |||
| 2020 | 3 980 | 3 980 | n/a | 8-Mar-23 | |||
| FSP – with performance conditions | |||||||
| 2017 | 15 540 | 14 409 | 1 131 | n/a | 71.50 | 23-Mar-20 | |
| 2017 | 1 131 | (1 131) | n/a | Lapsed | 23-Mar-20 | ||
| 2018 | 6 600 | 6 600 | n/a | 29-Jan-21 | |||
| 2019 | 9 400 | 9 400 | n/a | 26-Feb-22 | |||
| 2020 | 11 950 | 11 950 | n/a | 8-Mar-20 | |||
| CSP | |||||||
| 2020 | 41 320 | 41 320 | n/a | 8-Mar-23 | |||
| K Mmutlana | |||||||
| Share appreciation rights | |||||||
| 2018 | 32 540 | 32 540 | 177.71 | 29-Jan-21 | |||
| 2019 | 46 800 | 46 800 | 130.02 | 26-Feb-22 | |||
| FSP – no performance conditions | |||||||
| 2017 | 24 602 | 24 602 | n/a | 71.50 | 28-Mar-20 | ||
| 2018 | 1 300 | 1 300 | n/a | 29-Jan-21 | |||
| 2019 | 1 950 | 1 950 | n/a | 26-Feb-22 | |||
| 2020 | 3 640 | 3 640 | n/a | 8-Mar-23 | |||
| FSP – with performance conditions | |||||||
| 2017 | 8 198 | 7 602 | 596 | n/a | 71.50 | 23-Mar-20 | |
| 2017 | 596 | (596) | n/a | Lapsed | 23-Mar-20 | ||
| 2018 | 3 890 | 3 890 | n/a | 29-Jan-21 | |||
| 2019 | 5 840 | 5 840 | n/a | 26-Feb-22 | |||
| 2020 | 10 900 | 10 900 | n/a | 8-Mar-23 | |||
| CSP | |||||||
| 2020 | 37 690 | 37 690 | n/a | 8-Mar-23 |